In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Arianna Rodríguez-Coello *Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0007-5066-3020 Michelle Outeda-García *Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-6737-0239 Andrea García-PoseServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0005-1156-4199 Lucía Gonzalez-PintoServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-8387-3784 Gabriela Alejandra Báez-BarrosoServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0003-1042-8174 Paula Guijarro-SánchezServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-8456-0085 Andrea MurasServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0003-1603-9762 Biel TaltavullCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Pablo Fraile-RibotCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-3822-9965 Isaac Alonso-GarciaServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-1681-969X Antonio OliverServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0001-9327-1894 Juan Carlos Vázquez-UchaServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0003-4949-0779 Jorge Arca-SuárezServicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-4248-503X Germán Bou *Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0001-8837-0062 Alejandro Beceiro *Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-6340-7815 Funding
Axencia Galega de Innovación IN606A 2023/023Axencia Galega de Innovación IN606A-2024/033Axencia Galega de Innovación IN606B-2022/009Axencia Galega de Innovación IN607D 2024/008Axencia Galega de Innovación PI24/00920Instituto de Salud Carlos III CB21/13/00055Instituto de Salud Carlos III CB21/13/00099Instituto de Salud Carlos III CD23/00057Instituto de Salud Carlos III FI23/00074Instituto de Salud Carlos III FI24/00178Instituto de Salud Carlos III JR21/00026Instituto de Salud Carlos III JR23/00036Instituto de Salud Carlos III PI22/01212Instituto de Salud Carlos III PI23/00851Instituto de Salud Carlos III PI24/00920Instituto de Salud Carlos III PI25/00116Ministerio de Ciencia, Innovación y Universidades FPU24/02755Xunta de Galicia IN606A 2021/021
6 · The paper itselfAbstract
Chromosomal AmpC variants selected during ceftolozane/tazobactam or ceftazidime/avibactam therapy may affect cefiderocol activity. We evaluated the impact of the E219K substitution on cefiderocol efficacy using isogenic
Indexed as
Anti-Bacterial AgentsAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCeftazidimeCephalosporinsPseudomonas aeruginosaTazobactamAnimalsBacteremiaCefiderocolDrug CombinationsDrug Resistance, Multiple, BacterialMiceMicrobial Sensitivity TestsPenicillanic AcidAmpC beta-lactamasesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCefiderocolCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsPenicillanic AcidTazobactamThird Generation Cephalosporinscefiderocolceftazidime/avibactamceftolozane/tazobactamE219Kmurine infectionPDCPseudomonas aeruginosa
Identifiers
PMID42747386
PMCPMC13689382
What OpenQuestion holds
Textmetadata
Read underepoch 390